SCHEMBL7413136

SCHEMBL7413136

Cc1cc(C)c(S(=O)(=O)NCC(NS(=O)(=O)c2c(C)cc(C)cc2C)C(=O)NO)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53
MMP7 P09237 4/20 0.49
ITGAV P06756 5/20 0.48
MMP10 P09238 1/20 0.48
FABP4 P15090 1/20 0.47
NR3C1 P04150 4/20 0.44
PGR P06401 4/20 0.44
NR3C2 P08235 4/20 0.44
LMNA P02545 1/20 0.42
NR2F2 P24468 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7418672 0.90 MMP9 (0.57) MMP9CA1CA2MMP1MMP2
SCHEMBL7414547 0.87 MMP7 (0.54) MMP9CA1CA2MMP7MMP10
SCHEMBL7411120 0.87 MMP7 (0.54) MMP9MMP7MMP10
SCHEMBL7416539 0.86 MMP7 (0.61) MMP9MMP13MMP7MMP10MAPT
SCHEMBL7412866 0.86 MMP7 (0.61) MMP9CA1CA2MMP1MMP2
SCHEMBL7416682 0.85 MMP7 (0.58) MMP9CA1CA2MMP1MMP2
SCHEMBL7423461 0.85 MMP7 (0.58) MMP9CA1CA2MMP1MMP2
SCHEMBL31086909 0.84 CA1 (0.54) MMP9CA1CA2MMP1MMP2
SCHEMBL7411989 0.84 MMP7 (0.49) MMP9CA1CA2MMP1MMP2
SCHEMBL7414577 0.84 MMP7 (0.49) MMP9CA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed